Close Menu

NEW YORK (360Dx) – Siemens Healthineers has announced the commercial launch of a CE-marked immunoassay for Zika virus detection — the Novagnost Zika Virus IgM µ-capture Assay.

The firm said that the immunoassay enables enhanced patient outcomes through differential diagnostics in line with a World Health Organization test algorithm, and that the assay is available for sale in countries outside the US that accept the CE mark.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.